Form 8-K

8-K — Oncology Institute, Inc.

Accession: 0001079973-26-000997

Filed: 2026-08-03

Period: 2026-07-28

CIK: 0001799191

SIC: 8011 (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE)

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — toi_8k.htm (Primary)

EX-3.1 — CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (ex3x1.htm)

EX-99.1 — EXHIBIT 99.1 (ex99x1.htm)

GRAPHIC (image_001.jpg)

GRAPHIC (image_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: toi_8k.htm · Sequence: 1

Current Report

false

--12-31

0001799191

2026-07-28

0001799191

TOI:CommonStockParValue0.0001Member

2026-07-28

0001799191

TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember

2026-07-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

Form 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported) July 28, 2026

___________________________________

THE ONCOLOGY INSTITUTE, INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware

001-39248

84-3562323

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

18000 Studebaker Road, Suite 800, Cerritos, CA

90703

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code: (562) 735-3226

(Former name or former address, if changed since last

report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written

communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001

TOI

The Nasdaq Stock Market LLC

Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share

TOIIW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange

Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐.

Item 5.03 Amendments to Articles of Incorporation

or Bylaws; Change in Fiscal Year.

On July 28, 2026, The Oncology Institute,

Inc., a Delaware corporation (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment

(the “Certificate of Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation changing the

Company’s name from “The Oncology Institute, Inc.” to “Starling Oncology, Inc.”, effective immediately.

A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

Pursuant to Section 242 of the General Corporation

Law of the State of Delaware, no stockholder approval was required for the Certificate of Amendment because it only related to a name

change.

In connection with the name change, the Company’s

trading symbol for its common stock begins trading on the Nasdaq Stock Market LLC on August 3, 2026, as “STLN”.

Neither the name change, nor the symbol

change, affects the rights of the Company’s stockholders, and stockholders do not need to take any action in connection therewith.

The CUSIP number for the Company’s common stock remains 68236X100.

Item 7.01 Regulation FD Disclosure

On August 3, 2026, the Company issued a press

release announcing the name change and the symbol change from TOI to STLN. A copy of the press release is attached hereto as Exhibit 99.1

and is incorporated herein by reference.

The information in this Item 7.01, including

Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated

by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange

Act of 1934, as amended (the “Exchange Act”), except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description of Exhibit

3.1

Certificate of Amendment to

the Third Amended and Restated Certificate of Incorporation dated July 28, 2026

99.1

Press Release dated August 3, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of

1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 3, 2026

THE ONCOLOGY INSTITUTE, INC.

By:

/s/ Minh Merchant

Name:

Minh Merchant

Title:

Chief Legal Officer

EX-3.1 — CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

EX-3.1

Filename: ex3x1.htm · Sequence: 2

Exhibit 3.1

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ex99x1.htm · Sequence: 3

Exhibit

99.1

The Oncology Institute Rebrands as Starling Oncology

Company to begin trading on Nasdaq under new

ticker symbol “STLN,” replacing “TOI”

CERRITOS, Calif., Aug. 3, 2026 (GLOBE NEWSWIRE) – The Oncology

Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced

today that it has rebranded to “Starling Oncology, Inc.™.” The Company's common stock will begin trading under the new

ticker symbol "STLN” on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol “TOI.”

“We've spent the past several years rebuilding this organization,

reaching profitability, and scaling a technology-enabled, highly coordinated care model. We have proven that we have a better solution

for both payers and the patients who trust us with accessible, outcomes-focused, high-quality medical care," said Dan Virnich, MD,

MBA, FACHE, Chief Executive Officer of Starling Oncology. "Starling Oncology is a name that reflects our scale and our continued

upward trajectory as an organization. Like starlings in flight, our coordinated delivery model emphasizes accessibility and teamwork that

defines our commitment to community-based cancer care. Our name is changing, but our mission remains steadfast: delivering high-quality,

patient-centered cancer care to the communities we serve, with a focused ambition to help solve the cost crisis in oncology."

The rebrand marks an important milestone in the Company's continued

growth and reflects its evolution beyond a traditional oncology practice into an integrated oncology platform serving patients, providers,

and health plans across multiple markets.

As the Company rebrands, patients, payers and providers can expect the

same phone numbers, portal access, and points of contact throughout the transition, with no disruption to care.

About Starling Oncology:

Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing

oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute,

Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical

trials, transfusions, and other care delivery models traditionally associated with leading oncology organizations. With more than 400

employed and network clinicians and more than 100 clinics and network locations across five states and growing, Starling Oncology is coordinating

cancer care for the better. For more information, visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter),

or Bluesky.

Contacts:

Media

ICR Healthcare

StarlingPR@icrhealthcare.com

Investors

ICR Healthcare

StarlingIR@icrhealthcare.com

+++

GRAPHIC

Filename: image_001.jpg · Sequence: 4

Binary file (7710 bytes)

Download image_001.jpg

GRAPHIC

Filename: image_002.jpg · Sequence: 5

Binary file (68428 bytes)

Download image_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Jul. 28, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 28, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-39248

Entity Registrant Name

THE ONCOLOGY INSTITUTE, INC.

Entity Central Index Key

0001799191

Entity Tax Identification Number

84-3562323

Entity Incorporation, State or Country Code

Entity Address, Address Line One

18000 Studebaker Road

Entity Address, Address Line Two

Suite 800

Entity Address, City or Town

Cerritos

Entity Address, State or Province

Entity Address, Postal Zip Code

90703

City Area Code

(562)

Local Phone Number

735-3226

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock, par value $0.0001

Title of 12(b) Security

Common stock, par value $0.0001

Trading Symbol

TOI

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share

Title of 12(b) Security

Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share

Trading Symbol

TOIIW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=TOI_CommonStockParValue0.0001Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=TOI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: